01:11 PM EST - Glb Wellness Strategies : Announced the signing of a supply agreement with Canada-based PharmAla Biotech to supply GMP MDMA for the Shanti Therapeutics upcoming clinical trial. Global Wellness' Shanti Therapeutics is a first-in-class biotech utilizing the neuromodulation properties of MDMA to pre-emptively treat preoperative pain. Shanti has commenced a path to their clinical trial in 22 healthy volunteers comparing the pain tolerance threshold in patients who have had exposure to a proprietary dose and formulation of MDMA. This proof-of-concept study is to gauge the effect size of an increase in the pain threshold in subjects who have been pre-emptively treated with MDMA. Glb Wellness Strategies
shares C.GWS are trading unchanged at $0.26.
